0.13Open0.07Pre Close103 Volume1.98K Open Interest12.50Strike Price870.00Turnover148.10%IV10.09%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.10Extrinsic Value100Contract SizeAmericanOptions Type0.1583Delta0.2581Gamma152.60Leverage Ratio-0.0750Theta0.0001Rho24.16Eff Leverage0.0015Vega
Biomea Fusion Stock Discussion
trigger sold 1/4 during while market shaky
hope the diabetes study outcome rocket
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
Biomea Fusion, Inc. (Nasdaq: BMEA) announced that the FDA has lifted the clinical hold on its ongoing Phase I/II clinical trials of BMF-219, an investigational covalent menin inhibitor, for type 2 and type 1 diabetes(COVALENT-111 and COVALENT-112).
The company's CEO, Thomas Butler, expressed confidence in BMF-219 as a novel, first-in-class agent for diabetes treatment, noting that safety concern...
No comment yet